ALVO•benzinga•
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Summary
Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga